The US president says the levies on pharmaceutical imports are imminent, but won’t take effect for a year to a year and a ...

Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly ...

The Craigavon investment enhances Almac’s global clinical supply network with upgraded storage, distribution, and shipping ...

In the second part of his Pharma Commerce video interview, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, outlines how the ...

In the United States, Medicaid is considered the largest payer of healthcare, serving nearly a quarter of the total population; this includes nearly 40 million children. And in a separate analysis, ...

In a video interview with Pharma Commerce, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses the evolving state of global cell and gene therapy commercialization. Sawicki highlighted ...

Preparing for Federal Regulations: Q&A with John Stanford In an interview with Pharmaceutical Executive, John Stanford, executive director at Incubate, emphasized the importance of sustained ...

How CRO Partnerships Are Evolving to Meet Changing Industry Demands In an interview with Applied Clinical Trials, Judith Ng-Cashin, MD, chief medical officer, Novotech, emphasized the need for CRO ...

Key Takeaways Medically tuned AI systems can reduce literature review time by over 88%, boost accuracy beyond 96%, and detect safety signals months faster than manual methods, helping prevent adverse ...

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from ...

Key Takeaways Independent PAP foundations reduce legal risks and expand support. Structuring patient assistance programs as independent non-profit foundations helps pharmaceutical companies reduce ...

Strategic Planning in the Rebate Economy: What Pharma Must Do Now A recent Pharmaceutical Executive article outlines how, despite decades of evolving policy from OBRA ’90 to the Inflation Reduction ...